Becton, Dickinson and Company

BDX • Medical - Instruments & Supplies

$184.74

▼ -2.88 (-1.54%)

Current price

EarningsLatest report: Jun 30, 2026

BALANCED PROFILENeutralConfidence: 70%

Quantitative profile — not an investment recommendation.

Quantitative profile — not an investment recommendation.Methodology

Analysis thesis: Mixed profile. The company is not automatically unattractive, but valuation, growth, or balance-sheet evidence does not yet justify a stronger signal.

Market Cap

$52.02B

Growth

8.0%

Cash Flow

5/5

Trend

Stable

Evidence

Positive free cash flow · 9.32Consistent free cash flow · 5/5Manageable debt level · 0.76Negative growth trend

Financial data as of: Jun 30, 2026, 12:00 AM UTCLast earnings update: Jun 30, 2026, 12:00 AM UTCLast profile update: Aug 7, 2026, 12:16 PM UTC

Company Snapshot

Key valuation, quality, financial strength, momentum and analyst data.

Price$184.74

Change-1.54%

Shares Out281.60M

Market Cap$52.02B

Enterprise Value$65.83B

52W Range127.59 - 187.35

Beta0.27

P/E55.23

P/S2.59

P/B1.03

P/FCF19.06

EV/Sales3.28

Price$184.74

Change-1.54%

Shares Out281.60M

Market Cap$52.02B

Enterprise Value$65.83B

52W Range127.59 - 187.35

Beta0.27

P/E55.23

P/S2.59

P/B1.03

P/FCF19.06

EV/Sales3.28

EV/EBITDA52.96

EV/FCF24.11

Earnings Yield1.81%

FCF Yield5.25%

Dividend Yield1.69%

Gross Margin45.44%

Oper. Margin11.80%

Profit Margin7.68%

Debt/Eq0.76

Current Ratio1.11

Quick Ratio0.64

Revenue 5Y8.00%

Target$186.88

Target Upside1.16%

Target Median$190.00

Target Range159.00 - 210.00

Volume3.29M

Avg Volume2.73M

EPS Surprise0.12

Investment DNA

How strong this company looks for long-term investors

out of 100

Business Quality

Margins, moat, returns

57/100

Financial Strength

Debt, cash, stability

50/100

Growth Potential

Revenue and expansion

38/100

Price Attractiveness

Cheap or expensive today

76/100

Why this score▼

Positive free cash flow · 9.32Consistent free cash flow · 5/5Manageable debt level · 0.76Negative growth trend

Analyst view

Analyst sentiment and price target

BDX

Analyst sentiment

Based on 34 analyst votes · 2026-09-05

72/100

Bullish

Hold

Bearish

Price Target

2026-08-07

Low

$159.00

Mean

$183.57

Median

$180.00

High

$210.00

Company Overview

IPO: 2/21/1973

Industry: Medical - Instruments & Supplies

P/B i: 1.03

Debt / Equity i: 0.76

Operating Margin: 11.80%

Net Margin: 7.68%

ROE i: -

ROIC: -

Financial Health

Score10 / 20

Debt / Equity: 0.76

Current Ratio: 1.11

Quick Ratio: 0.64

Status: Moderate

Warnings

Weak quick ratio

Insider Transactions

Recent executive and insider activity

Byington Carrie L

Transaction: 08/06/2026

BUY

Change

+94

Price

Not reported

Filing

08/06/2026

Type

BUY

Huffines Robert Luther

Transaction: 08/06/2026

BUY

Change

+189

Price

Not reported

Filing

08/06/2026

Type

BUY

Feld Michael

Transaction: 07/27/2026

SELL

Change

-75

Price

$157.13

Filing

07/28/2026

Type

SELL

Insider	Type	Change	Price	Transaction	Filing
Byington Carrie L	BUY	+94	Not reported	08/06/2026	08/06/2026
Huffines Robert Luther	BUY	+189	Not reported	08/06/2026	08/06/2026
Feld Michael	SELL	-75	$157.13	07/27/2026	07/28/2026
Muhsin Bilal	SELL	-1,935	Not reported	07/02/2026	07/06/2026
Muhsin Bilal	BUY	+14,342	Not reported	07/01/2026	07/06/2026
Feld Michael	SELL	-75	$152.80	06/26/2026	06/26/2026
Garrison Michael David	SELL	-1,100	$145.66	06/24/2026	06/25/2026
Sinha Manish	OTHER	0	Not reported	06/22/2026	06/22/2026
Sinha Manish	OTHER	+2,663	$168.49	11/26/2025	06/22/2026
Sinha Manish	OTHER	+3,147	$179.49	11/26/2024	06/22/2026
Sinha Manish	OTHER	+3,408	$178.86	11/26/2023	06/22/2026
Sinha Manish	OTHER	+3,555	$181.15	11/26/2022	06/22/2026
Sinha Manish	OTHER	+5,690	$168.13	11/26/2021	06/22/2026
Sinha Manish	OTHER	+4,441	$188.63	11/26/2020	06/22/2026
Sinha Manish	OTHER	+4,100	$178.94	11/26/2019	06/22/2026
Sinha Manish	OTHER	+4,174	$167.25	11/26/2018	06/22/2026
Garrison Michael David	SELL	-1,100	$151.48	06/10/2026	06/11/2026
Polen Thomas E Jr	SELL	-20,209	$126.16	06/01/2026	06/03/2026
Polen Thomas E Jr	SELL	-17,445	$146.15	06/01/2026	06/03/2026
Menziuso Peter	OTHER	0	Not reported	06/01/2026	06/02/2026

About the Company

Becton, Dickinson and Company

Operating globally, Becton, Dickinson and Company (BD) is a prominent enterprise focused on the development, manufacturing, and distribution of a broad spectrum of medical technology. This includes essential medical supplies, sophisticated devices, advanced laboratory equipment, and critical diagnostic products. Its extensive customer base comprises healthcare providers, clinical institutions, medical researchers, pharmaceutical firms, and the general public around the world. The BD Medical division delivers a comprehensive suite of products primarily focused on medication management and drug delivery. This encompasses a variety of intravenous (IV) access solutions, such as peripheral and advanced catheters, central lines, acute dialysis catheters, and related vascular care items including needle-free connectors and closed-system drug transfer devices. It also provides essential injection equipment like hypodermic syringes, needles, anesthesia trays, enteral syringes, and sharps disposal systems. Additionally, this segment develops integrated systems for IV medication and infusion therapy, medication compounding workflow, automated dispensing, and supply chain optimization. Specialized products for diabetes management, including pen needles, along with prefillable drug delivery systems, are also key offerings. BD Life Sciences focuses on diagnostic and research tools, offering products for specimen and blood collection. This segment supplies automated systems for culturing blood and tuberculosis, molecular testing, microorganism identification, and drug susceptibility analysis. It also provides liquid-based cytology systems, rapid diagnostic assays, microbiology laboratory automation, and plated media. Furthermore, it offers advanced solutions for cell analysis, including fluorescence-activated cell sorters and analyzers, antibodies, kits, and reagent systems. These are crucial for single-cell gene expression analysis, as well as for clinical oncology, immunological, and transplantation diagnostics and monitoring. Finally, the BD Interventional segment delivers specialized products for surgical and interventional procedures. Its portfolio includes solutions for hernia and soft tissue repair, biological and bioresorbable grafts, and biosurgery, alongside other surgical products. This segment also addresses surgical infection prevention, provides a range of surgical and laparoscopic instrumentation, offers peripheral intervention products, and supplies urology and critical care devices. Established in 1897, the company maintains its headquarters in Franklin Lakes, New Jersey.

Source - link

Peers

A ALC ARGX CAH EW HLN IDXX IQV RMD VEEV

Size reflects market cap · color matches the chart line

1Y peer performance

Top performers + selected company

Latest news

BDX DCF Analysis: Intrinsic Value $157 vs Price $187

On September 02, 2026, we delve into the DCF analysis for Becton Dickinson and Co (BDX), a company that has shown notable price performance with a year-to-date in

GuruFocus

Two Recessions Couldn't Stop These 4 Healthcare Stocks From Raising Dividends

Two brutal recessions wiped out dividends across the market, yet a handful of healthcare companies kept raising their payouts through every quarter of both downturns.

24/7 Wall Street

Jim Cramer Calls This Mining Stock an Inflation Hedge “Just as Good as Crypto”

On a recent edition of CNBC's Mad Money Lightning Round, Jim Cramer fielded questions from viewers. Two of Cramer's clearest calls were to buy Vale (NYSE:VALE | VALE Price Prediction) as an inflation hedge comparable to cryptocurrency and to stay long Apple (NASDAQ:AAPL) through an upcoming leadership change.

24/7 Wall Street

BD Extends Leadership in Advanced Tissue Regeneration Through Continued Clinical Innovation

STANCE trial surpasses a key enrollment milestone, advancing the clinical evaluation of GalaFLEX LITE™ Scaffold and generating evidence to support its use in breast revision surgery for capsular contracture FRANKLIN LAKES, N.J., Aug. 27, 2026 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced a significant milestone in its advanced tissue regeneration strategy and expansion efforts with the STANCE clinical trial evaluating GalaFLEX LITE™ Scaffold in breast revision surgery for capsular contracture.

PRNewsWire

BD to Present at Wells Fargo 21st Annual Healthcare Conference

FRANKLIN LAKES, N.J., Aug. 26, 2026 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that it will present at the Wells Fargo 21st Annual Healthcare Conference on Wednesday, September 9, 2026, at 9:30 a.m.

PRNewsWire

Earnings Surprises

Period	Estimate	Actual	Surprise
2026-05-07	2.78	2.9	0.12
2026-02-09	2.21	2.91	0.7
2025-11-06	3.92	3.96	0.04
2025-08-07	3.4	3.68	0.28
2025-05-01	3.28	3.35	0.07
2025-02-05	3	3.43	0.43
2024-11-07	3.77	3.81	0.04
2024-08-01	3.31	3.5	0.19
2024-05-02	2.97	3.17	0.2
2024-02-01	2.4	2.68	0.28
2023-11-09	3.42	3.42	0
2023-08-03	2.89	2.96	0.07